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PODIUM SESSION I: ECONOMIC EVALUATIONS I
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DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH
CARE DECISIONS: DOES HIERARCHICAL INFORMATION
INTEGRATION OFFER A SOLUTION?
Van Helvoort-Postulart D1, Dellaert B2,Van der Weijden T3,
Von Meyenfeldt M1, Dirksen CD1
1Maastricht University Medical Center, Maastricht,The Netherlands,
2Erasmus University Rotterdam, Rotterdam,The Netherlands,
3Maastricht University, Maastricht,The Netherlands
OBJECTIVES: Discrete choice experiments (DCE) are increas-
ingly used to investigate preferences for health care products and
programs. A limitation of DCE is the inability to handle large
numbers of attributes. In hierarchical information integration
(HII) attributes are categorized into meaningful subsets, and
separate experiments are designed for each of the subsets. A
HII-DCE was applied regarding potential barriers and facilita-
tors to implementation of the guideline for breast cancer surgery
in day-care. METHODS: A total of 1713 questionnaires were
sent to three groups of health care professionals (anesthesiolo-
gists, surgical oncologists, breast care nurses). Random param-
eters logit modelling was used to estimate a choice model.
Theoretical validity, construct validity, and internal consistency
were assessed to investigate whether HII can be used to deal with
the typical complexity of multi-faceted health care management
decisions. Also, response rate and predictive ability of the model
were assessed to study the feasibility of HII. RESULTS: Sixteen
out of 17 attributes were signiﬁcant at the 1% level and had the
expected sign. Also all three decision constructs were signiﬁcant
at the 1% level, and were well deﬁned by their attributes. The
test-retest resulted in a Kappa statistic of 0.58 (p < 0.001). The
overall response rate was 10%. The predicted frequency distri-
bution and observed frequency distribution based on the full
proﬁle hold-out task did not differ signiﬁcantly (Chi-square test;
p = 0.088). CONCLUSIONS: Our study showed good theoreti-
cal validity, good construct validity and satisfactory internal con-
sistency. Response rate was poor and predictive ability of the
model was satisfactory. In conclusion, HII can be successfully
used to study complex health care decisions. The feasibility of
HII in this particular context of an implementation decision
seemed less favourable.
EE2
STANDARDIZEDTYPE 2 DIABETES COMPLICATION COSTS
FROM US COMMERCIAL PAYERSTO BE USED IN MODELING
THE LONG-TERM ECONOMIC OUTCOMES OF DIABETES
COMPLICATIONS
Minshall ME1, Pelletier EM2, Smith PJ3, Forma FM4
1IMS Health, Noblesville, IN, USA, 2IMS Health Consulting,
Watertown, MA, USA, 3PharMetrics, a unit of IMS,Watertown, MA,
USA, 4Novo Nordisk Inc, Princeton, NJ, USA
OBJECTIVES: The American Diabetes Association (ADA) has
estimated the annual cost of diabetes in the USA at $174 billion
(ADA, Diabetes Care, 2008), using multiple and varied sources
to derive cost estimates. This study used a single, multi-payer US
database to derive private payer-speciﬁc estimates of average type
2 diabetes mellitus (T2DM) complication costs, which may be
suitable for long-term economic modeling. METHODS: Private
health insurance claims were taken from the PharMetrics Patient-
Centric Database, which is comprised of adjudicated medical and
pharmaceutical claims covering 55 million unique patients from
over 90 health plans from across the USA. T2DM patients expe-
riencing at least 1 of 24 major complications from July 1, 2003
through June 30, 2005, along with a T2DM diagnosis prior to or
on the date of the index complication, were identiﬁed. T2DM
complication costs were extracted from 64,556 patients who had
a minimum of 12 months follow-up. Cost data for months 13–24
following the complication were taken from a subset of the full
patient population who were continuously eligible for at least 24
months (n = 47,541). Direct medical costs were subdivided into
charges and allowed amounts expressed in $US 2007. RESULTS:
The average age of the population was 57 years and 51.8% were
male. The most frequently reported complication was peripheral
neuropathy (26.3%). First year charges for complications ranged
between $272 for ketoacidosis to $38,588 for myocardial infarc-
tion, with corresponding allowed amounts of $174 and $14,394,
respectively. Second year charges for complications ranged
between $0 for ketoacidosis to $21,965 for peritoneal dialysis,
with corresponding allowed amounts of $0 and $10,133, respec-
tively. Among all complications, allowed amounts were sig-
niﬁcantly lower than charged amounts. CONCLUSIONS: Our
study provides an important and representative source of T2DM
complication costs for estimating the long-term economic impact
of this prevalent and costly disease.
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VARIATION IN DIRECT MEDICAL COSTS BY DISEASE
SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS
CVIRUS
Davis KL1, Mitra D1, Medjedovic J2, Beam C3, Rustgi V4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis
Pharma AG, Basel, Switzerland, 3Human Genome Sciences, Inc,
Rockville, MD, USA, 4Georgetown University Medical Center, Fairfax,
VA, USA
OBJECTIVES: To document disease-related resource utilization
and costs by disease severity among persons with chronic hepatitis
C virus (HCV) in a United States (US) managed care population.
METHODS:AUS insurance claims database spanning January 1,
2002 toDecember 31, 2006was retrospectively analyzed. Patients
with1 diagnosis of chronic HCV and no evidence of hepatitis B
were selected. Patients had continuous plan enrollment for 6
months before and 12 months following ﬁrst observed HCV
diagnosis. Disease severity, measured using the aspartate ami-
notransferase to platelet ratio index (APRI), was assessed for
patients with valid lab results (N = 2877). Patients were classiﬁed
into three mutually exclusive severity categories: mild (APRI 
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0.5, N = 2384), moderate (0.5 < APRI&LE;1.5, =″/″ and=″″
(apri=″″ severe=″″ n=″377),″>1.5, N = 116). Per patient use and
costs of HCV-related medical services and prescriptions were
assessed over 12 months post-diagnosis. RESULTS: More than
23% of patients with severe HCV had a disease-related hospital-
ization compared to 12%and 16%ofmild andmoderate patients,
respectively (both P < 0.05). Hospitalization costs were nearly
2.5 times higher in moderate patients ($3480) and approximately
4.7 times higher in severe patients ($6872) compared to thosewith
mild disease ($1448; both P < 0.01). Severe patients also had a
signiﬁcantly (P < 0.01) higher mean number of hospital days (7.9)
compared to moderate (6.7 days) and mild patients (4.1 days).
There were no signiﬁcant differences in encounters and costs for
physician ofﬁce and emergency department visits. Severe patients
had slightly lower (but insigniﬁcant) HCV-related pharmacy costs
compared to mild and moderate patients. After controlling for
demographics and comorbidities in a multivariate analysis, mild
patients incurred $4708 less (P < 0.01) in total HCV-related costs
compared to severe patients. CONCLUSIONS: Patients with
moderate and severe HCV incur nearly twice the medical costs of
patients with mild disease, due primarily to increased hospitaliza-
tions. There was no signiﬁcant difference in ambulatory resource
use and costs between moderate and severe patients.
EE4
CAREER INTERRUPTIONS AND SICK LEAVES AMONG
FIBROMYALGIA PATIENTS
Le Lay K1, Boussetta S1, Moldofsky H2,Taieb C1
1Pierre Fabre, Boulogne, France, 2Centre for Sleep and
Chronobiology,Toronto, ON, Canada
OBJECTIVES: Early diagnosis of ﬁbromyalgia and its manage-
ment represent a public health issue for the health authorities
who allocate resources. Career interruptions and absences from
work consume a signiﬁcant share of these resources.The aim was
to describe the characteristics of subjects who reported career
interruptions or sick leaves in UK, METHODS: Four question-
naires, the LFESSQ (London Fibromyalgia Epidemiology Study
Screening Questionnaire), the CES-D (Center for Epidemiologic
Studies Depression Scale), the SQA (Sleep Quality Assessment),
and the FMQ (Fibromyalgia Moldofsky Questionnaire), were
administered to a representative community sample in UK. A
descriptive analysis of career interruptions and sick leaves was
carried out using social and demographic data and symptoms
supplied by the subjects surveyed, RESULTS: 25.1% stated that
they were not working at the time of the survey, with signiﬁcantly
more women (34.3% vs 15.5%), subjects over 50 (50.5% vs
4.9%) and with a low income (58.2% vs 45.9%). Subjects with
pain (LFESSQ positive), a strong presumption of ﬁbromyalgia
syndrome (FMQ > 8), with an unrestorative sleep (SQA >= 14),
a possible depressive symptoms (CES-D > 17) were signiﬁcantly
more frequently inactive. 24.8% had been absent during the last
year (average of 8.6 absence days). Subjects with pain, a strong
presumption of ﬁbromyalgia, an unrestorative sleep, a possible
depressive symptoms were not more frequently absent from
work. The number of absence days increased signiﬁcantly with
the number of concomitant symptoms: 1 day for subjects expe-
riencing pain, 1.8 for subjects with a sleep disorder, 3.3 for pain
and fatigue, 3.8 for pain and probable depressive symptoms,
reaching 5.1 days for a combination of pain, fatigue and prob-
able depressive symptoms, CONCLUSIONS: Career interrup-
tions were signiﬁcantly more common in subjects who screened
positive on the LFES-SQ and who had a strong presumption of
ﬁbromyalgia syndrome, whereas absence from work mostly
affected subjects with a sleep disorder.
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HEALTH ECONOMIC ANALYSIS OF CONTINUOUS
SUBCUTANEOUS INSULIN INFUSION COMPAREDTO
MULTIPLE DAILY INJECTIONS FORTHETREATMENT OF
TYPE 1 DIABETES IN POLAND
Clegg JP1,Wéry E1, Karamalis M2, Pokorski J2, Mlynarski W3,
Valentine WJ1
1IMS Health, Allschwil, Switzerland, 2Medtronic Poland Sp. z o.o,
Warsaw, Poland, 3Medical University of Lodz, Lodz, Poland
OBJECTIVES: To evaluate the long-term clinical and economic
outcomes of treating adults and adolescents with type 1 diabetes
with continuous subcutaneous insulin infusion (CSII) versus mul-
tiple daily injections (MDI) in Poland. METHODS: A validated
model was used to estimate the lifetime impact of CSII-related
improvements in diabetes control on quality-adjusted life-
expectancy (QALE), occurrence of complications, and direct
medical costs in two Polish type 1 diabetes cohorts (Adult—mean
age 37.8 years, duration of diabetes 10.4 years, mean HbA1c
9.40%; adolescent—mean age 14.0 years, duration of diabetes
1.0 year, mean HbA1c 9.40%, no baseline complications). Treat-
ment effects of CSII were deﬁned from a meta-analysis as a
reduction of 0.95% in HbA1c and a decrease in severe hypogly-
cemia (14.8 versus 62 events per 100 patient-years) compared
with MDI. Future costs and beneﬁts were discounted at 5%
annually and projected over the patient’s lifetime. All costs were
evaluated in 2006 Polish Zloty and converted to Euro (€).
RESULTS: CSII was associated with improvements in QALE
(0.35 and 0.46 quality-adjusted life-years [QALYs] for adults and
adolescents, respectively) and fewer diabetes-related complica-
tions versus MDI. Over patient’s lifetime CSII versus MDI for
adults and adolescents was projected to reduce the cost of renal
disease by €865 and €413 and cost of hypoglycaemia by €576
and €3,463, respectively. For adults and adolescents CSII was
projected to cost €9,309 and €19,294 more than MDI over a
patient’s lifetime, respectively. CSII was associated with an incre-
mental cost-effectiveness ratio (ICER) of €20,778 for adults and
€14,968 for adolescents per QALY gained versus MDI. CON-
CLUSIONS: Based on the threshold proposed by the World
Health Organization (4 times the Gross Domestic Product per
capita, approximately €26,000), CSII treatment improves clinical
outcomes and represents a cost-effective treatment option com-
pared with MDI for patients with type 1 diabetes in Poland.
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